LivaNova
Manufacturing · United Kingdom · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
20 Eastbourne Terrace, London, Greater L...Phone Number
+44 2033250660Website
www.livanova.comRevenue
$1.5 BillionStock Symbol
LIVNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About LivaNova
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales represeRead more
LivaNova Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is LivaNova your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at LivaNova
Click to see if LivaNova had a recent Job posting/layoffs
Check if LivaNova has recently received funding, and reach out quickly before it becomes old news!
Check out if LivaNova is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on LivaNova recently announced quarterly report
Funding: Get notified immidiatlly once LivaNova has new funding data
LivaNova, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when LivaNova launches new products
Recommended Actions
Find VP level buyers at LivaNova
Find 2 more new buyers
Explore company insights
Get a deeper look into LivaNova's structure, leadership, and market position:
Company Profile Activity
Activity Insights
LivaNova is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
LivaNova is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about LivaNova.
LivaNova Tech Stack
A closer look at the technologies used by LivaNova
Most Recent Scoops
Earnings
LivaNova has reported adjusted free cash flow of $46 million for Q2 2026, compared to $48 million in the prior year period, with capital spend in H1 2026 increasing to $46 million from $26 million in the prior year period, driven by Cardiopulmonary capacity expansion, next-generation oxygenator manufacturing scale-up, and IT infrastructure investments.
Earnings, Facilities Relocation/Expansion, Spending/Investment, Capacity Planning, Finance, Manufacturing Operations
Project
LivaNova has announced plans to launch a next-generation oxygenator, designed to deliver enhanced gas transfer efficiency, low pressure drop, and strong platelet preservation to reduce blood trauma and improve patient outcomes, with launch expected in 2028 following ongoing manufacturing scale-up and facility expansion.
Product Development
Project
LivaNova has announced the development of a single shared cloud digital health platform spanning its entire portfolio including epilepsy, OSA, depression, and Cardiopulmonary with the epilepsy implementation already delivering workflow and connectivity benefits, and a next-generation implantable pulse generator featuring remote titration expected to launch in 2027.
Cloud, Product Development, Digital Technology, Healthcare Technology
Partnership
LivaNova has entered into a long-term agreement with Thermo Fisher Scientific to secure access to a critical oxygenator component, with the partnership expected to increase manufacturing output, capture underserved demand, and deliver benefits over the medium to long term.
Partnership, Product Development
Project
Laboratory Operations, Medical Research, Clinical Operations
LivaNova News & Media
LivaNova Director Sells 1,650 Shares for $131,500
The insider sold 1,650 shares but still retains nearly 8,000 shares.LivaNova PLC (LIVN) Q2 2026 Earnings Call Transcript
LivaNova PLC (LIVN) Q2 2026 Earnings Call August 5, 2026 8:00 AM EDTCompany ParticipantsBriana Gotlin - Vice President of Investor RelationsVladimir...LivaNova Q2 Earnings Call Highlights
LivaNova (NASDAQ:LIVN) reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjust
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding LivaNova
Sign Up For FreeTo access detailed company insights
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines,... Read More
